Page 774 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )
P. 774
758 Index
Trombocytopenia (Continued) Uremia, 517 predisposing actor, 573
immune thrombocytopenia, 512–513, 512t Urobilinogen, 132 risk actor, 573
increased utilization o platelets, 512 Urokinase, 533 vHCL (see Hairy cell leukemia-variant)
pathophysiologic classi cation, 509b Viscoelastic tests, 539
petechiae/purpura, 509 V Viscosity, 640
platelet distribution and dilution, disorders o , Vaccine, 378 Visual uorescent screening test, G6PD, 681
513–514 Vacuolated lymphocytes, 196 Vitamin B 12
platelet actor, 510, 511 Vacuoles, 340t, 342 de ciencies, 282b, 284, 286
production disorders, 509–510, 509b Vacuolization, 98 physiology, 283
thrombocytosis, 515–516 Variance, 17 potential causes, 287b
thrombotic thrombocytopenic purpura ( P), Variant lymphocytes, 193–194, 196, 196–197 transport, 283–284
513 Vascular abnormalities Vitamin B de ciency anemia, 258
12
Trombocytosis, 496, 515 bleeding disorders, 507–508, 508 Vitamin K antagonist, 575
Tromboelastography, 539–540, 540 blood vessel mal ormations, 505–506 Volume, conductivity and scatter (VCS), 625
Trombomodulin, 541 ecchymosis, 505, 505 von Willebrand disease (vWF)
Trombophilia, 563 hereditary hemorrhagic telangiectasia (HH ), classi cation o , 554, 554t
Trombopoiesis 505–506 clinical signs and symptoms, 555
bone marrow megakaryocytes, 493, 493 mechanical orce, 505 epidemiology, 554
endoreduplication, 493 petechiae, 504–505, 505 etiology, 553–554
mature platelets, 494–495, 495 purpura, 505 increased levels, 556
cellular ultrastructure o , 494–495, 495 purpura associated with in ections, 508 laboratory ndings, 556
megakaryocytes, 494, 494, 494t purpura related to miscellaneous causes, 508 nomenclature, 553, 553t
platelet kinetics, li e span, and normal values, vascular obstruction, 506–507, 506t, 507 pathophysiology, 554–555
495–496 vasculitis, 506 primary hemostasis, 556, 556t
Trombosis, 490 Vasculature physiology type I, 555, 556t
activated clotting actors and particulate endothelium role type II, 556, 556t
material removal, 541 endothelial dys unction, 492 type III, 556, 556t
activator and inhibitor, 545 endothelial unctions, 491, 492t von Willebrand’s disease, 521–522, 522t
body against thrombosis, 541 endothelins, 492
cellular regulators, 544–545 prothrombotic-antithrombotic balance, W
natural anticoagulant systems 491, 491t Waldenström macroglobulinemia (WM), 430
antithrombin (A ), 541 vasoconstrictor-vasodilator balance, 491, 491t clinical signs and symptoms, 441
actor V (leiden), 543–544 vascular integrity maintenance, 492 epidemiology, 440
heparin co actor, 541 vasoconstriction, 491 laboratory data, 441, 441
laboratory ndings, 543 Vasoconstriction, 491 pathophysiology, 440
protein C, 541–543, 542, 543t Vasoocclusion, 316 treatment and prognosis, 441
protein C testing, 543 VCS technology, 626B Waldenström primary macroglobulinemia (see
protein S, 544, 544t Venipuncture Lymphoplasmacytic lymphoma)
protein S testing, 544 per orming o , 41–42 War arin, 528, 534, 574
normal blood ow, 541 preparation, 40–41 Westergren method, erythrocytes sedimentation
Trombotic hemostasis panel assays, 639, 639b site, 40 rate, 678–679
T rombotic thrombocytopenic purpura ( P), 513 Venous blood collection WHO classi cation (see World Health
Tromoboelastometry, 539 basilic vein, 39 Organization (WHO) classi cation)
Tymus, 189 cephalic vein, 39 Whole blood cell analysis
issue actors, 530 complications automated cell counting instruments types,
issue hypoxia, 105 anemia, 45 624–627, 627
otal leukocyte count, 216–217, 223b cardiovascular, 44–45 Beckman-Coulter, 625–626, 626b
otal leukocyte count procedure, 591 dermatological, 45 Cell-Dyn Series, 624–625
oxic granulation, 339t, 341, 341 in ections, 44 Horiba ABX Diagnostics, Inc., 625
oxoplasmosis, 360–361 neurological, 45 Siemens Healthcare Diagnostics, 625
raditional cyanmethemoglobin ow-cell method, vascular, 44 Sysmex, 626
624 dialysis patients, 40 calculated output, 624, 624t
rait, 314 edema, 39 histogram characteristics, 627
rans errin, 124, 132 initiation, 38 instrument data output, 626–627, 627
rans errin receptor 2 ( R2), 271 IV lines, 40 output data, quality assurance o , 627
rans errin receptors ( R), 124–125 locating and drawing, 42–43 Sysmex lavender top hematology and diabetes
ransient erythroblastopenia o childhood ( EC), mastectomy patient, 40 testing solution, 624, 624
249 median cubital vein, 39 Wintrobe method, erythrocytes sedimentation
ranslocation, 65b patients rate, 679
ransudates, 592 children, 43 Wiskott-Aldrich syndrome (WAS), 514–515, 515
ransudates and exudates, 592, 592t geriatric patients, 43–44 World Health Organization (WHO) classi cation,
raumatic conditions, 239 pediatric patients, 43 373, 476, 477t
rend, 18 postmastectomy patient, 40 World Health Organization (WHO) Organization
rend line analysis, 19 problems, 42 classi cation, 382–383, 384b
ripotassium ethylenediaminetetraacetate (K procedure, 41 Wright-stain, 28
3
ED A), 28 procedure termination, 42
risomy, 65–66 scarring/burn, 40 X
rophozoites, 154, 155 site selection, 38–39 X-linked enzymopathy, 299
ube guide, 714–715 supplies and equipments, 38 Xanthochromia, 586
ube Guide Greiner, 716–717 veins arm, 39 Xerocytosis, hereditary, 297–298
ubulin, 62 venipuncture
umor-suppressing genes, 374–375 per orming o , 41–42 Y
site, 40, 40–41 Yolk sac, 82, 86
U site preparation, 40–41
Umbilical cord blood (UCB), 90–91 Venous thromboembolism (V E), 573, 573t Z
Unconjugated bilirubin, 132 congenital plasminogen de ciency, 574 Ziemann stippling, 155
Unstable hemoglobins, 328 hyperhomocysteinemia, 574 Zymogen, 541
